Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III revumenib plus intensive chemotherapy in newly diagnosed NPM1-mutated AML
ISRCTN42617850Phase 3Recruiting
- Sponsor
- Syndax Pharmaceuticals
- Start
- Mar 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial in acute myeloid leukemia (AML) comparing Experimental Arm: Revumenib + Intensive Chemotherapy with Placebo + Intensive Chemotherapy (2 arms). Primary endpoints: Event-Free Survival and Minimal Residual Disease in Bone Marrow Negative Complete Response Rate. Started Mar 2026; status: recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ISRCTN42617850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN42617850.